Authors
Latest:
Future-Ready Leadership: Redefining the Biopharma C-suite for an AI-Driven EraHow will the tasks of C-suite leaders be transformed by intelligent technologies?
Latest:
How to Stand Out in the Wellness Space as a Pharma BrandKey steps in relationship-building beyond just treatment options.
Latest:
Defending Against Label-Based LawsuitsBest practices for defending against lawsuits based on pharmaceutical labeling, including avenues for early resolution of the case and, as necessary, strategies for developing the best evidence for defense.
Latest:
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based ProductsAs the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
Latest:
How COVID-19 Has Affected Launches of New Oncology Therapies in the U.S.Several months into the COVID-19 pandemic, this article takes a look back at how the launches of new oncology therapies have been impacted.
Latest:
IDN Trends, Insights and Strategies Every Manufacturer Should KnowWebinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT
Latest:
How and Why the New ‘Over-Time’ Is Transforming the Work of Medical AffairsWhat’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.
Latest:
The Tech Perspective: Coordinating a Plan of EngagementDesigning an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.
Latest:
Evolving a Market Access Strategy to Improve Patient AccessDavid Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.
Latest:
Hybrid Hub Models for the Patient JourneyJosh Marsh, Vice President and General Manager of Cardinal Health Sonexus™ Access and Patient Support, outlines the recent shift in the patient services industry towards a hybrid hub model for in-house management and outsourced support.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Market Access Speed Is the Next Critical Differentiator for Pharma ManufacturersNew technology forces industry to increase urgency.
Latest:
Food for Thought: Make Room for Multiple OpinionsThe rise of DOLs doesn’t mean pharma should upend KOL approach.
Latest:
Advancing Innovation in Cancer Care: Bringing the Next Wave of Oncology Products to MarketWhile the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.
Latest:
Drug Launch: Winning the Evidence BattleBeyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
Latest:
A Better Way to Combat Patent TrollsCross-sector businesses are banding together to protect their intellectual property, but there’s a better way to do it.
Latest:
Partnering to Respond to a Possible Nuclear ThreatRecent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Latest:
How Does the Shift to Early-Stage M&A Change Due Diligence?A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.
Latest:
Applying the Scientific Method as the Cornerstone of Brand StrategyHow commercial teams can benefit from a more scientifically rigorous approach to insights generation
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
Maximizing China Access for Innovative TherapiesTo maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.
Latest:
Proactive Engagement: How AI-Driven Alerts are Transforming HCP OutreachThe benefits for brand teams in bolstering their rapid-response capability.
Latest:
Positioning Medical Information as a Trust Driver for Your BrandFour steps to maximize the impact of medical information services as an engagement gateway.
Latest:
Despite Slowing Economy, Demand for Pharma Talent RisesPharma companies need to rethink their strategies to ensure that they hire the best available talent in today's market.
Latest:
Almirall’s Garden of InnovationClay Hausmann describes how Almirall is weeding out uncertainty to sow the seeds of data-driven digital transformation.
Latest:
Regeneron Faces FDA Setbacks with CRL for Odronextamab, Delays on Eylea HD BLA Amid Third-Party Manufacturing IssuesRegeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD due to inspection findings at a Catalent manufacturing site, despite continued strong revenue growth and pipeline momentum.
